Loss of p16 as result of gene promoter methylation is not associated with disease stage or prognosis, thus suggesting its early occurrence in gastrinoma pathogenesis [31, 32]. This evidence concerns the gene CDKN2A and gastrin-producing neuroendocrine tumor.